Please login to the form below

Not currently logged in
Email:
Password:

meningococcal B disease

This page shows the latest meningococcal B disease news and features for those working in and with pharma, biotech and healthcare.

Pfizer wins EU approval for MenB vaccine Trumenba

Pfizer wins EU approval for MenB vaccine Trumenba

The EU approval comes two-and-a-half years after Trumenba was green-lighted by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitides serogroup B, which is ... It is important to have multiple tools at our disposal to

Latest news

  • Pfizer posts positive Trumenba vaccine data Pfizer posts positive Trumenba vaccine data

    Pfizer's Trumenba vaccine for meningitis B has shown favourable results in two phase III trials. ... Trumenba was approved by the FDA in 2014 to prevent invasive meningococcal disease caused by Neisseria meningitides serogroup B.

  • Pfizer gets FDA nod for meningitis vaccine Trumenba Pfizer gets FDA nod for meningitis vaccine Trumenba

    Trumenba - formerly known as rLP2086 - has been approved by the FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in people aged 10 to 25, a strain which ... Invasive meningococcal disease is a life-threatening

  • US panel backs pneumococcal vaccines for seniors US panel backs pneumococcal vaccines for seniors

    The ACIP recommendations now go to the Centers for Disease Control and Prevention (CDC) and Department of Health and Human Services (DHHS) for review and approval. ... Separately, Pfizer also said that the FDA has accepted its marketing application for

  • Pfizer's meningitis vaccine 'a breakthrough' Pfizer's meningitis vaccine 'a breakthrough'

    Aside from the risk of death, meningococcal B disease can also lead to long-term disabilities such as brain damage and hearing loss. ... The breakthrough therapy designation highlights the urgent need for prevention of meningococcal B disease," he added.

  • Research into meningococcal B disease Research into meningococcal B disease

    Multicomponent meningococcal serogroup B vaccine or 4CMenB (Bexsero, Novartis) was approved in the EU for the immunisation against invasive meningococcal disease (IMD) caused by the bacterium Neisseria meningitidis serogroup B in ... Looking ahead.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...

Infographics